Volume 16, Number 1—January 2010
Pandemic (H1N1) 2009 Reinfection, Chile
Highlight and copy the desired format.
|EID||Perez CM, Ferres M, Labarca JA. Pandemic (H1N1) 2009 Reinfection, Chile. Emerg Infect Dis. 2010;16(1):156-157. https://dx.doi.org/10.3201/eid1601.091420|
|AMA||Perez CM, Ferres M, Labarca JA. Pandemic (H1N1) 2009 Reinfection, Chile. Emerging Infectious Diseases. 2010;16(1):156-157. doi:10.3201/eid1601.091420.|
|APA||Perez, C. M., Ferres, M., & Labarca, J. A. (2010). Pandemic (H1N1) 2009 Reinfection, Chile. Emerging Infectious Diseases, 16(1), 156-157. https://dx.doi.org/10.3201/eid1601.091420.|
To the Editor: Since March 2009, influenza A pandemic (H1N1) 2009 has spread worldwide (1), and in South America, Chile was 1 of the countries most affected by the pandemic, with 21.4 cases among every 1,000 persons. Treatment guidelines in Chile recommended antiviral drug treatment with oseltamivir or zanamivir for 5 days for all patients with confirmed or suspected virus subtype H1N1 infection (2). In persons with seasonal influenza, specific antibody responses reach peak titers by 4 weeks after infection and confer protection against the infecting strain and closely related strains (3). Reinfection is rarely seen in nonpandemic influenza A. We report on 3 patients with confirmed influenza A pandemic (H1N1) 2009 reinfection after successful treatment with oseltamivir.
Patient 1, a healthy 14-year-old girl, had fever, sore throat, and nasal congestion on clinical examination. Pandemic (H1N1) 2009 infection was diagnosed by viral culture and confirmed by PCR specific for subtype H1N1 (LightMix Kit Inf A swine H1; TIB MOLBIOL, Berlin, Germany, for Roche Diagnostic, Indianapolis, IN, Light Cycler 2.0 instrument). The patient received oseltamivir, and symptoms resolved 48 hours after treatment. Twenty days later, fever, muscle aches, and vomiting developed in the patient. Influenza A virus was isolated by viral culture. The patient received a preliminary diagnosis of seasonal influenza and was treated with amantadine. She recovered from the infection before PCR results confirmed it was caused by pandemic (H1N1) 2009 virus.
Patient 2, a 62-year-old woman, experienced a high fever, cough, and nasal congestion during a prolonged hospitalization for bowel resection after intestinal ischemia. Pandemic (H1N1) 2009 was confirmed by PCR and viral culture. Oseltamivir was administered 5 days after the onset of symptoms, and the symptoms resolved within the following 5 days. The patient had a new episode of fever, productive cough, and bronchial obstruction 2 weeks later while still hospitalized. Culture results were positive for influenza, and PCR results were positive for pandemic (H1N1) 2009. The patient was again treated with oseltamivir, and PCR results were negative for influenza after 48 hours of antiviral treatment.
Patient 3, a previously healthy 38-year-old man, underwent mitral and aortic valve replacement while hospitalized for acute mitral and aortic endocarditis due to Staphylococcus aureus. Eleven days after surgery, he had a sore throat, nasal congestion, cough, and low-grade fever. PCR test results were positive for pandemic (H1N1) 2009. The patient received oseltamivir, and respiratory symptoms resolved within 5 days. He was discharged from the hospital but was readmitted 18 days later with nasal congestion, cough, and high fever. PCR results were again positive for pandemic (H1N1) 2009, and the patient was successfully treated with oseltamivir.
Patient 2 and probably patient 3 acquired their infections while hospitalized, suggesting potential nosocomial transmission. No other respiratory viruses were found in any of these patients. The viral isolates were all tested (LightMix for detection of influenza A virus oseltamivir resistance [H274Y]; TIB MOLBIOL) for possible resistance to oseltamivir, but none had the resistance-implicated H274Y mutation in the neuraminidase gene
Shedding of seasonal influenza A virus ceases within 5–7 days during natural infection and during infections treated with neuraminidase inhibitors (4). Although clearing of virus after the first infection was not documented in the 3 patients described here, it is unlikely that virus persisted between the 2 episodes of influenza since each of the patients fully recovered after specific antiviral drug treatment. However, we cannot rule out that patient 2 may have never cleared the virus due to her immune suppression.
As described by mathematical modeling (5), the 3 patients described were susceptible to reinfection with pandemic (H1N1) 2009 due to the high rate of community infection and to their incomplete immunologic protection within the period of reexposure. During the current pandemic of influenza subtype H1N1, healthcare workers and patients should be aware that symptomatic reinfection might occur after a first episode of infection.
- World Health Organization. Pandemic (H1N1) 2009—update 58 [cited 2009 Jul 12]. Available from http://www.who.int/csr/don/2009_07_06/en/index.html
- Ministerio de Salud. Influenza [in Spanish] [cited 2009 Sep 14]. Available from http://www.redsalud.gov.cl/portal/url/page/minsalcl/g_varios/influenza.html
- Treanor JJ. Influenza virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. New York: Elsevier; 2005. p. 2060–85.
- Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects of antiviral treatment.J Clin Virol. 2009;44:255–61.
- Gökaydin D, Oliveira-Martins JB, Gordo I, Gomes MG. The reinfection threshold regulates pathogen diversity: the case of influenza.J R Soc Interface. 2007;4:137–42.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Carlos Miguel Perez, Pontificia Universidad Catolica de Chile – Medicine, Marcoleta 357, Santiago 00000, Chile
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 31, 2011
- Page last updated: March 31, 2011
- Page last reviewed: March 31, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)